Debra Hughes, MS

Debra (Lumpe) Hughes has more than 3 decades of oncology medical writing and editing experience, including as a former editor of Oncology Times. She has a diverse background in medical journalism, education, and publishing. Her company, D.A. Hughes & Associates, provides medical communications services for academic institutions, communications and publishing companies, global pharmaceutical and biotechnology corporations, and professional medical associations and societies. Debra is an alumna of Columbia University Graduate School of Journalism, where she specialized in science writing, and the University of California, Riverside.

Most Recent Articles by Debra Hughes, MS

FDA Grants First Tissue/Site Agnostic Indication to Pembrolizumab

FDA Grants First Tissue/Site Agnostic Indication to Pembrolizumab

By

The FDA has granted accelerated approval for the agency's first tissue/site agnostic indication to pembrolizumab.

FDA Approves Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma

FDA Approves Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma

By

The FDA granted regular approval to pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following chemotherapy.

Second-line Atezolizumab Fails To Prolong Survival in Advanced Urothelial Cancer

Second-line Atezolizumab Fails To Prolong Survival in Advanced Urothelial Cancer

By

It's unclear whether the FDA will revoke its May 2016 approval of atezolizumab, which was based on tumor response rate and duration of response in the phase 2 open-label IMvigor210 study.

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

By

Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.

FDA Approves Avelumab for Urothelial Carcinoma

FDA Approves Avelumab for Urothelial Carcinoma

By

The US Food and Drug Administration has approved avelumab for locally advanced or metastatic urothelial carcinoma.

More Articles by Debra Hughes, MS

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters